Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | EVP, PRESIDENT, DRUG DELIVERY | June 30, 2026 | July 02, 2026 |
| Savara IncSVRA · Entity 4900 | Director | December 19, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,592 |
Ending reported balance
After 2026-06-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-30 · Exercise / conversion · Acquired 10,000 · Balance 10,000 Row 2 · 2026-06-30 · Tax withholding · Disposed 5,408 · Balance 4,592 F1: The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-30 · Exercise / conversion · Disposed 10,000 · Balance 0 F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,232 |
Reported balance
After 2026-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-01 · Grant · Acquired 16,232 · Balance 16,232 F3: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $77.01 · Expires 2036-07-01 | Direct | 39,823 |
Reported balance
After 2026-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-01 · Grant · Acquired 39,823 · Balance 39,823 F4: This option vests one-fourth on such date and then 1/48th monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date.
F3: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
F4: This option vests one-fourth on such date and then 1/48th monthly thereafter.
Savara Inc
Report date December 19, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,533,642 |
Reported balance
After 2025-12-19 transaction · row 1
1 source rowRow 1 · 2025-12-19 · Sale · Disposed 20,000 · Balance 2,533,642 F1: Represents shares sold to satisfy tax liability upon the vesting of restricted stock units. F2: The price is a weighted average sales price. The sale prices ranged from $6.04 to $6.08. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold to satisfy tax liability upon the vesting of restricted stock units.
F2: The price is a weighted average sales price. The sale prices ranged from $6.04 to $6.08. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LA JOLLA PHARMACEUTICAL CO
Report date August 22, 2022 · Filed August 24, 2022
Section 16 reporting ended · disclosed 2022-08-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 1
1 source rowRow 1 · 2022-08-22 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.81 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $4.53 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 20:45 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 39,823 | $0.00 Strike: $77.01 | $0.00 |
DisclosureSEC source: 0001159036-26-000096 · wk-form4_1783025152.xml · derivative · entry 5 RAMSAY DAVID A · CIK 0001283292 · EVP, PRESIDENT, DRUG DELIVERY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,823 Underlying: Common Stock · 39,823 shares Expires 2036-07-01 F4 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:45 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 16,232 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000096 · wk-form4_1783025152.xml · derivative · entry 4 RAMSAY DAVID A · CIK 0001283292 · EVP, PRESIDENT, DRUG DELIVERY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,232 Underlying: Common Stock · 16,232 shares Expires not disclosed F3 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F3 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:45 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000096 · wk-form4_1783025152.xml · derivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · EVP, PRESIDENT, DRUG DELIVERY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:45 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 5,408 | $78.27 | $423,284.16 |
DisclosureSEC source: 0001159036-26-000096 · wk-form4_1783025152.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · EVP, PRESIDENT, DRUG DELIVERY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,592 F1 · shares: The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:45 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000096 · wk-form4_1783025152.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · EVP, PRESIDENT, DRUG DELIVERY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 22:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000047 · wk-form4_1775168956.xml · derivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_date: This award vests in full on June 30, 2026 provided the Reporting Person remains employed through such date and is subject to a one-year holding period from the vesting date. F1 · derivative.expiration_date: This award vests in full on June 30, 2026 provided the Reporting Person remains employed through such date and is subject to a one-year holding period from the vesting date. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:00 UTC | Savara Inc SVRA · Entity 4900 | SaleCommon Stock | 20,000 | $6.06 | $121,220.00 |
DisclosureSEC source: 0001193125-25-327035 · ownership.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,533,642 F1 · shares: Represents shares sold to satisfy tax liability upon the vesting of restricted stock units. F2 · price: The price is a weighted average sales price. The sale prices ranged from $6.04 to $6.08. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 22:45 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-316299 · ownership.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,553,642 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on December 9, 2026, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 11:00 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 150,000 | $2.78 | $416,250.00 |
DisclosureSEC source: 0000950170-25-048032 · ownership.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,513,642 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $2.75 to $2.80. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 22:40 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-136768 · ownership.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,363,642 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on December 12, 2025, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 18, 2024 17:33 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 100,000 | $2.88 | $287,600.00 |
DisclosureSEC source: 0000950170-24-127869 · ownership.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,323,642 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $2.85 to $2.91. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 22:37 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058848 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,223,642 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on December 14, 2024, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 26, 2023 Filed May 26, 2023 15:31 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 37,124 | $2.63 | $97,599.00 |
DisclosureSEC source: 0001209191-23-032391 · doc4.xml · nonDerivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,201,142 F3 · price: The price is a weighted average purchase price. The purchase prices ranged from $2.60 to $2.66. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 25, 2023 Filed May 26, 2023 15:31 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 12,876 | $2.57 | $33,129.95 |
DisclosureSEC source: 0001209191-23-032391 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,164,018 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $2.55 to $2.59. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 24, 2023 Filed May 26, 2023 15:31 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 50,000 | $2.56 | $127,800.00 |
DisclosureSEC source: 0001209191-23-032391 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,151,142 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $2.54 to $2.57. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 17:41 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 29,000 | $1.55 | $44,834.00 |
DisclosureSEC source: 0001209191-23-000057 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,101,142 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.49 to $1.58. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 17:41 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 7,000 | $1.54 | $10,752.00 |
DisclosureSEC source: 0001209191-23-000057 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,072,142 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.48 to $1.55. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 28, 2022 Filed Dec 28, 2022 21:40 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 3,293 | $1.50 | $4,923.04 |
DisclosureSEC source: 0001209191-22-062838 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,065,142 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.48 to $1.51. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 21:40 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 15,707 | $1.44 | $22,665.20 |
DisclosureSEC source: 0001209191-22-062838 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,061,849 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.43 to $1.45. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 22, 2022 Filed Dec 22, 2022 20:19 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 41,414 | $1.48 | $61,127.06 |
DisclosureSEC source: 0001209191-22-062420 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,046,142 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.45 to $1.50. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 20, 2022 Filed Dec 20, 2022 18:29 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 13,830 | $1.50 | $20,758.83 |
DisclosureSEC source: 0001209191-22-062125 · doc4.xml · nonDerivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,001,142 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.485 to $1.53. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 20:19 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 3,586 | $1.48 | $5,307.28 |
DisclosureSEC source: 0001209191-22-062420 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,004,728 Read SEC document |
| December 19, 2022 Filed Dec 20, 2022 18:29 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 40,719 | $1.49 | $60,834.19 |
DisclosureSEC source: 0001209191-22-062125 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,987,312 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.47 to $1.52. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 18:29 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 341 | $1.50 | $511.50 |
DisclosureSEC source: 0001209191-22-062125 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,946,593 Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:10 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001209191-22-061418 · doc4.xml · derivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-12-13 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable on December 13, 2023. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 13:30 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 4,610 | $1.44 | $6,633.79 |
DisclosureSEC source: 0001209191-22-058760 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,946,252 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.43 to $1.46. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 13:30 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 15,495 | $1.42 | $22,018.40 |
DisclosureSEC source: 0001209191-22-058760 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,941,642 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.41 to $1.429. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 21:39 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 25,005 | $1.42 | $35,532.11 |
DisclosureSEC source: 0001209191-22-058171 · doc4.xml · nonDerivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,926,147 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.34 to $1.47. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 21:39 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 16,100 | $1.34 | $21,606.20 |
DisclosureSEC source: 0001209191-22-058171 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,901,142 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.31 to $1.36. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 21:39 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 8,900 | $1.27 | $11,303.00 |
DisclosureSEC source: 0001209191-22-058171 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,885,042 Read SEC document |
| September 27, 2022 Filed Sep 27, 2022 16:49 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 73,893 | $1.37 | $101,381.20 |
DisclosureSEC source: 0001209191-22-051327 · doc4.xml · nonDerivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,876,142 F3 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.35 to $1.42. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 26, 2022 Filed Sep 27, 2022 16:49 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 31,107 | $1.38 | $43,052.09 |
DisclosureSEC source: 0001209191-22-051327 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,802,249 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.36 to $1.39. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 23, 2022 Filed Sep 27, 2022 16:49 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 30,000 | $1.42 | $42,660.00 |
DisclosureSEC source: 0001209191-22-051327 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,771,142 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.40 to $1.46. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 20, 2022 Filed Sep 20, 2022 20:08 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 600 | $1.45 | $870.00 |
DisclosureSEC source: 0001209191-22-050703 · doc4.xml · nonDerivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,741,142 Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 20:08 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 1,400 | $1.46 | $2,039.80 |
DisclosureSEC source: 0001209191-22-050703 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,740,542 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.45 to $1.46. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 20:08 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 6,000 | $1.44 | $8,652.00 |
DisclosureSEC source: 0001209191-22-050703 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,739,142 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.427 to $1.46. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 08, 2022 Filed Sep 8, 2022 19:37 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 29,000 | $1.40 | $40,571.00 |
DisclosureSEC source: 0001209191-22-049138 · doc4.xml · nonDerivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733,142 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.38 to $1.404. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 07, 2022 Filed Sep 8, 2022 19:37 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 2,130 | $1.39 | $2,950.05 |
DisclosureSEC source: 0001209191-22-049138 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,704,142 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.38 to $1.39. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 19:37 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 870 | $1.38 | $1,200.60 |
DisclosureSEC source: 0001209191-22-049138 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,702,012 Read SEC document |
| September 01, 2022 Filed Sep 1, 2022 20:37 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 39,768 | $1.42 | $56,470.56 |
DisclosureSEC source: 0001209191-22-048251 · doc4.xml · nonDerivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,701,142 F3 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.38 to $1.45. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 31, 2022 Filed Sep 1, 2022 20:37 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 39,494 | $1.42 | $56,199.96 |
DisclosureSEC source: 0001209191-22-048251 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,661,374 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.38 to $1.46. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 20:37 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 20,738 | $1.41 | $29,261.32 |
DisclosureSEC source: 0001209191-22-048251 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,621,880 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.38 to $1.43. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:22 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $4.81 | Not disclosed |
DisclosureSEC source: 0000899243-22-029662 · doc4.xml · derivative · entry 5 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:22 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy · Derivative | 30,000 | Not disclosed Strike: $4.53 | Not disclosed |
DisclosureSEC source: 0000899243-22-029662 · doc4.xml · derivative · entry 4 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:22 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $3.93 | Not disclosed |
DisclosureSEC source: 0000899243-22-029662 · doc4.xml · derivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:22 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,000 | Not disclosed Strike: $8.43 | Not disclosed |
DisclosureSEC source: 0000899243-22-029662 · doc4.xml · derivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:22 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerCommon Stock | 100,000 | $6.23 | $623,000.00 |
DisclosureSEC source: 0000899243-22-029662 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document |
| June 22, 2022 Filed Jun 22, 2022 17:23 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 39,000 | $1.45 | $56,355.00 |
DisclosureSEC source: 0001209191-22-038640 · doc4.xml · nonDerivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601,142 F3 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.438 to $1.45. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 17:23 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 21,094 | $1.38 | $29,109.72 |
DisclosureSEC source: 0001209191-22-038640 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562,142 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.30 to $1.39. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 17:23 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 39,906 | $1.33 | $52,915.36 |
DisclosureSEC source: 0001209191-22-038640 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541,048 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.30 to $1.34. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.